Fosun moves on from debt crisis with renewed focus on tourism, healthcare
The conglomerate is looking to take Fosun Tourism and Henlius private as its finances improve, helped by asset sales Key Takeaways: In his New Year’s speech, Fosun founder Guo Guangchang…
Henlius finds elixir in first profits, scraps A-share IPO
The drug maker said last week it will halt plans for a second listing on China’s STAR Market, the same day it announced its first-ever interim profit since its 2019…
Biosimilar Specialist Henlius Takes Off. Now Comes the Hard Part
Fosun Pharma-backed company posts huge revenue jump in the second half of last year, as it boosts production and signs more global licensing deals to stay ahead of competition Key…
RELATED ARTICLES
-
Fosun Tourism travels back to home base with delisting plan
1992.HK 0656.HK -
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
Property crisis deepens with debt action against Sunac
1918.HK
-
Country Garden’s debt restructure hinges on stabilizing property market
2007.HK
-
BRIEF: Fosun Tourism may have dropped into the red last year
1992.HK
-
BRIEF: Fosun pledges 27% of Fosun Pharma’s A-shares
2196.HK 600196.SHG
-
Battered Lanvin hopes for better 2025 as executive revolving door keeps turning
LANV.US
